NanoViricides Prices $2 Million Registered Direct Offering to Fund Antiviral Development

NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions. This financing underscores continued institutional interest in NanoViricides' innovative antiviral platform.

The proceeds will support the development of NV-387, a broad-spectrum antiviral drug that has received Orphan Drug Designation (ODD) from the U.S. FDA Office of Orphan Products Development. This designation provides potential benefits including seven years of market exclusivity upon approval, tax credits for clinical trial costs, and fee exemptions. NV-387 is designed as a host-mimetic nanomedicine that viruses and their variants cannot easily escape, targeting a wide range of respiratory viral illnesses. The drug has demonstrated high efficacy in lethal animal infection models for influenza, RSV, coronaviruses, monkeypox, smallpox, and measles, positioning it as a potential first-line treatment for patients presenting with respiratory viral symptoms.

The offering highlights NanoViricides' progress in advancing its clinical-stage pipeline. The company's technology platform aims to address the challenge of viral evolution by mimicking host cell receptors, thereby neutralizing viruses regardless of mutations. This approach could offer a significant advantage over traditional antivirals that often face resistance. The $2 million capital injection will likely accelerate ongoing studies and manufacturing preparations, bringing NV-387 closer to potential commercialization. For more details, the full press release is available at https://ibn.fm/Z8Etj.

Investors and industry observers will be watching for updates on NV-387's clinical trial progress, as the drug's broad-spectrum activity could fill an important gap in pandemic preparedness and routine respiratory illness management. The offering's structure, with warrants exercisable at a premium to the current stock price, suggests confidence from the institutional investor in the company's long-term prospects. NanoViricides continues to leverage its nanomedicine expertise to develop antivirals that may reduce the burden of seasonal and emerging viral threats. Further information on the company and its developments can be found in its newsroom at https://ibn.fm/NNVC.